Discover
ANIX
Anixa Biosciences, Inc.
3.14
2 x 2.24
2 x 3.62
bid
ask
+
0.34
12.14%
2 @ 06:21 AM
3.14 +0.00 (0.14%)
| Ytd | 0.64% | |
| 1y | -2.79% |
2.74
day range
3.21
2.32
52 week range
5.46
| Open | 2.76 | Prev Close | 2.80 | Low | 2.74 | High | 3.21 | Mkt Cap | 106.83M |
| Vol | 395.78K | Avg Vol | 161.18K | EPS | -0.30 | P/E | N/A | Forward P/E | -7.17 |
| Beta | 0.85 | Short Ratio | 3.03 | Inst. Own | 17.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-10 | 50-d Avg | 2.79 | 200-d Avg | 3.30 | 1yr Est | 8.50 |
ANIX News
benzinga.com
Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breas
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
prnewswire.com
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protec
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South
benzinga.com
Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary E
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
prnewswire.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Posit
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w
zacks.com
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys
benzinga.com
Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Techn
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven